FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY
MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.
Projectdetails
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite recent advances, cancer therapies remain ineffective and/or highly toxic.
Approach
Our approach is targeting MYC, a function essential to cancer cells that allows them to survive and develop resistance to therapy. In contrast to standard drugs, inhibiting MYC selectively blocks tumor progression without causing important side effects. MYC has been considered undruggable for a long time, and no clinical MYC inhibitor is yet marketed.
Drug Development
Peptomycs first-in-class drug, OMO-103, is a cell-penetrating mini-protein that derives from Omomyc, the best MYC inhibitor known to date. OMO-103 recently completed a Phase 1 clinical trial that confirmed its safety and clinical activity in all-comers solid tumor patients, causing a 49% tumor shrinkage in a PDAC patient and stabilizing the disease of 8 out of 12 evaluable patients.
Biomarker Identification
Moreover, using AI, we identified predictive and pharmacodynamic circulating biomarker signatures, and generated companion diagnostic tests for stratification and real-time response monitoring for OMO-103. OMO-103 and its companion diagnostic tests offer a promising therapeutic option for a disease in great need and could apply to treat many other cancer indications.
Future Goals
The next steps and goals of this MYCureX project consist of:
- Conducting a Phase 1b trial in 1st-line PDAC patients, combining OMO-103 with the standard of care, to evaluate its safety and clinical activity.
- Refining the companion diagnostic prototypes and app.
- Securing the scale-up of the innovation by developing a commercial-scale compatible manufacturing process.
- Expanding the applications of OMO-103 and Peptomyc's drug pipeline.
Conclusion
By completing MYCureX, Peptomyc will consolidate the therapeutic potential of MYC inhibition in cancer patients, improving their survival and quality of life while establishing itself as a European leader biotech in MYC targeting.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.494.504 |
Totale projectbegroting | € 3.563.578 |
Tijdlijn
Startdatum | 1-7-2023 |
Einddatum | 31-12-2025 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PEPTOMYC SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)iOnctura aims to accelerate clinical trials for IOA-289, a novel autotaxin inhibitor targeting pancreatic cancer, to improve treatment outcomes and attract further investment. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approachTUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M. | EIC Accelerator | € 2.462.533 | 2024 | Details |
Multi-omic data driven drug discovery and indication prioritisation platform in oncologymCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies. | EIC Accelerator | € 2.495.788 | 2022 | Details |
The ProM platform: New ways to drug the undruggablePROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer. | EIC Accelerator | € 2.461.375 | 2022 | Details |
Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)
iOnctura aims to accelerate clinical trials for IOA-289, a novel autotaxin inhibitor targeting pancreatic cancer, to improve treatment outcomes and attract further investment.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach
TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.
Multi-omic data driven drug discovery and indication prioritisation platform in oncology
mCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies.
The ProM platform: New ways to drug the undruggable
PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Maximizing the use of a first clinically viable MYC inhibitorThis project aims to enhance the therapeutic potential of the MYC inhibitor Omomyc by exploring its delivery methods and combination therapies for treating brain tumors and understanding MYC biology. | ERC Advanced... | € 2.499.904 | 2024 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerDe ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Actionable metabolite supplements to improve treatment response in pancreatic cancerThe ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients. | ERC Proof of... | € 150.000 | 2024 | Details |
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal AdenocarcinomaPROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity. | ERC Consolid... | € 1.999.401 | 2023 | Details |
Curing ovarian cancer through autoantibody-based therapyThis project aims to develop a novel MUC16-specific antibody drug conjugate (2B5-ADC) for ovarian cancer therapy, enhancing efficacy and targeting while preparing for phase 1 clinical trials. | ERC Proof of... | € 150.000 | 2024 | Details |
Maximizing the use of a first clinically viable MYC inhibitor
This project aims to enhance the therapeutic potential of the MYC inhibitor Omomyc by exploring its delivery methods and combination therapies for treating brain tumors and understanding MYC biology.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.
Actionable metabolite supplements to improve treatment response in pancreatic cancer
The ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients.
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma
PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.
Curing ovarian cancer through autoantibody-based therapy
This project aims to develop a novel MUC16-specific antibody drug conjugate (2B5-ADC) for ovarian cancer therapy, enhancing efficacy and targeting while preparing for phase 1 clinical trials.